Plasminogen activator inhibitor type 1 deficiency

Haemophilia

Volumn 14, Issue 6, 2008, Pages 1255-1260

  Mehta, Rakesh ^a   Shapiro, A D ^b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antifibrinolytic agents; Bleeding; Dysproteinaemia; Fibrinolysis; Menorrhagia; Plasminogen activator inhibitor type 1

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANEXAMIC ACID;

ANTIGEN DETECTION; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; EPISTAXIS; FIBRINOLYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; INCIDENCE; MENORRHAGIA; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATOR INHIBITOR 1 DEFICIENCY; POSTOPERATIVE HEMORRHAGE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ANTIGENS; CHILD; CHILD, PRESCHOOL; FEMALE; FIBRINOLYSIS; HEMORRHAGE; HEMORRHAGIC DISORDERS; HETEROZYGOTE; HUMANS; INFANT; MALE; MENORRHAGIA; MIDDLE AGED; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREVALENCE; RARE DISEASES; YOUNG ADULT;

EID: 55949086898     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01834.x     Document Type: Article

References (28)

1. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-40.
2. van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-21.
3. Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
4. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
5. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989; 83: 1747-52.
6. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EK. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 1991; 77: 528-32.
7. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 1992; 327: 1729-33.
8. Agren A, Wiman B, Stiller V et al. Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis. J Thromb Haemost 2006; 4: 201-8.
9. Kuhli C, Luchtenberg M, Scharrer I, Hattenbach LO. Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefes Arch Clin Exp Ophthalmol 2005; 243: 963-6.
10. Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993; 81: 2357-62.
11. Minowa H, Takahashi Y, Tanaka T et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis 1999; 29: 286-91.
12. Morimoto Y, Yoshioka A, Imai Y et al. Haemostatic management of intraoral bleeding in patients with congenital deficiency of alpha2-plasmin inhibitor or plasminogen activator inhibitor-1. Haemophilia 2004; 10: 669-74.
13. Repine T, Osswald M. Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: Case report and literature review. Clin Appl Thromb Hemost 2004; 10: 293-6.
14. Santamaria A, Borrell M, Mateo J, Vallve C, Fontcuberta J. What is the clinical impact of low plasminogen activator inhibitor-1 (PAI-1) activity? A case report and study of the incidence of low PAI-1 antigen in a healthy population. J Thromb Haemost 2007; 5: 1565-6.
15. Takahashi Y, Tanaka T, Minowa H et al. Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol 1996; 64: 61-8.
16. Tanimura LK, Weddell JA, McKown CG, Shapiro AD, Mulherin J. Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: Case report. Pediatr Dent 1994; 16: 133-5.
17. Zhang ZY, Wang ZY, Dong NZ et al. A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. Blood Coagul Fibrinolysis 2005; 16: 79-84.
18. Booth NA, Bachmann F. Plasminogen-plasmin system. In: Coleman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams and Wilkins, 2006: 335-64.
19. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res 2001; 103(Suppl. 1): S7-19.
20. Yepes M, Loskutoff DJ, Lawrence DA. Plasminogen activator inhibitor-1. In: Coleman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams and Wilkins, 2006: 365-80.
21. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-6.
22. Agren A, Wiman B, Schulman S. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis 2007; 18: 657-60.
23. Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: Characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 1997; 90: 204-8.
24. Kahl BS, Schwartz BS, Mosher DF. Profound imbalance of pro-fibrinolytic and anti-fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: Correction by liver transplantation. Blood Coagul Fibrinolysis 2003; 14: 741-4.
25. Agren A, Kolmert T, Wiman B, Schulman S. Low PAI-1 activity in relation to the risk for perioperative bleeding complications in transurethral resection of the prostate. Thromb Res 2007; 119: 715-21.
26. Durand MK, Bodker JS, Christensen A et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004; 91: 438-49.
27. Leissner P, Verjat T, Bachelot T et al. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer 2006; 6: 216.
28. Bajou K, Noel A, Gerard RD et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-8.